Impact Biotech Ltd. has entered into an agreement with Maastricht University to collaborate on research focused on eye treatment to arrest the progression of pathological myopia, also known as myopic ...

Novartis has been given a green light in the EU for the use of its Lucentis product in the treatment of pathological myopia, a major cause of vision loss. Specifically, Lucentis (ranibizumab) has been ...

Expert Rev Ophthalmol. 2008;3(3):311-323. Choroidal neovascularization in PM has been treated with different approaches, which include laser photocoagulation, submacular surgery, photodynamic therapy ...

Myopia is the most common eye disease worldwide, with prevalence rates of 25-50% among adults in the United States and Europe and up to 85-90% among young people in Asian countries. In East Asia, ...

Please provide your email address to receive an email when new articles are posted on . The expanding myopia epidemic and the increasing number of children who develop myopia at a young age will ...

Myopia is the most common eye disease worldwide, with prevalence rates of 25-50% among adults in the United States and Europe, and up to 85-90% among young people in Asian countries. In East Asia, ...

A condition causing progressive vision loss is receiving more attention as diagnoses rise, especially among younger populations with severe nearsightedness. Myopic macular degeneration presents a ...

Cataract surgery in the highly myopic patient, typically defined by an axial length greater than 26 mm, represents one of the ...

Myopia, more commonly known as nearsightedness, is a condition due to the physical length of the eye being relatively too long for its refractive components. Despite its strong family trait, juvenile ...

The short-term use of atropine eye drops to treat myopia in children did not affect long-term visual outcomes, the prospective observational ATLAS study of participants from two randomized trials ...

Expert Rev Ophthalmol. 2008;3(3):311-323. The new and promising strategies for treating CNV include the use of drugs against VEGF, in particular isoform A, which is the most potent promoter of ...